ZYUS Life Sciences Corp. is a Canadian-based life sciences company. The company is headquartered in Saskatoon, Saskatchewan. The company went IPO on 2000-10-18. The company develops and commercializes novel cannabinoid-based pharmaceutical drug candidates for pain management. Its lead research program is focused on developing a highly purified cannabinoid formulation to treat chronic pain due to cancer, musculoskeletal injuries and arthritis. Its pre-and non-clinical studies provide the foundation for clinical investigations of its drug candidates in humans. Its lead/first drug product candidate in this program, Trichomylin softgel capsules, is a fixed dose combination of cannabinoids formulated for treatment of chronic pain in adults. This formulation offers oral administration of highly purified cannabinoids in a controlled dosage. In parallel with the research conducted respecting Trichomylin softgel capsules, it has also identified and commenced research on a second drug candidate. This drug candidate is a cannabinoid-based therapeutic composition for pain management.
Follow-Up Questions
What is the price performance of ZLSCF stock?
The current price of ZLSCF is $0.5323, it has decreased 0% in the last trading day.
What are the primary business themes or industries for ZYUS Life Sciences Corp?
ZYUS Life Sciences Corp belongs to Pharmaceuticals industry and the sector is Health Care
What is ZYUS Life Sciences Corp market cap?
ZYUS Life Sciences Corp's current market cap is $41.5M
Is ZYUS Life Sciences Corp a buy, sell, or hold?
According to wall street analysts, 5 analysts have made analyst ratings for ZYUS Life Sciences Corp, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
